Literature DB >> 20965978

Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial.

Serge Masson1, Aneta Aleksova, Chiara Favero, Lidia Staszewsky, Marino Bernardinangeli, Chiara Belvito, Giovanni Cioffi, Gianfranco Sinagra, Carmine Mazzone, Federico Bertocchi, Tarcisio Vago, Giuseppe Peri, Ivan Cuccovillo, Nobuhito Masuda, Simona Barlera, Alberto Mantovani, Aldo P Maggioni, Maria Grazia Franzosi, Marcello Disertori, Roberto Latini.   

Abstract

BACKGROUND: Inflammation may play a significant role in the pathogenesis of atrial fibrillation (AF).
OBJECTIVES: To examine the roles of three systemic inflammatory markers in predicting recurrent AF.
METHODS: The association between the plasma concentrations of high-sensitivity C reactive protein (hsCRP), interleukin-6 (IL-6) and pentraxin-3 (PTX3) with echocardiographic parameters and with the time to first recurrence of AF was tested in 382 patients with a history of AF but in sinus rhythm at randomisation, enrolled in the GISSI-AF biohumoral study.
RESULTS: Baseline PTX3 was related to left atrial, but not to left ventricular chamber volume. During one year of follow-up, 204 patients (53.1%) had a recurrent AF. There were no significant differences in baseline median [Q1-Q3] plasma concentrations of IL-6, hsCRP and PTX3 among patients with (2.11 [1.47-3.74] pg/ml, 3.30 [1.40-6.80] mg/l and 4.66 [3.27-6.97] ng/ml, respectively) or without recurrent AF (2.09 [1.37-2.90] pg/ml, p=0.182; 3.00 [1.10-6.20] mg/l, p=0.333; 5.09 [3.22-7.98] ng/ml, p=0.637). At 6 and 12 months follow-up, AF patients had significantly higher concentrations of IL-6 and PTX3 than those in sinus rhythm, and those with most recent episodes of AF had higher hsCRP. Baseline levels of IL-6, hsCRP or PTX3 were not significantly associated with a higher risk of recurrence of AF.
CONCLUSION: In patients with a history of AF, but without significant left ventricular dysfunction or heart failure, inflammatory biomarkers may be raised but are, at best, weak predictors of the risk for first recurrence of AF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20965978     DOI: 10.1136/hrt.2009.191460

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  14 in total

Review 1.  Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation.

Authors:  John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal
Journal:  Expert Rev Cardiovasc Ther       Date:  2018-12-29

2.  High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial.

Authors:  Jessica M Peña; Jean MacFadyen; Robert J Glynn; Paul M Ridker
Journal:  Eur Heart J       Date:  2011-12-20       Impact factor: 29.983

3.  Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation.

Authors:  Hiromasa Katoh; Tsuyoshi Nozue; Ichiro Michishita
Journal:  Heart Vessels       Date:  2017-03-10       Impact factor: 2.037

4.  Interleukin-37 elevation in patients with atrial fibrillation.

Authors:  Weidong Li; Shijie Li; Xianjin Li; Shuzhong Jiang; Bing Han
Journal:  Clin Cardiol       Date:  2016-11-02       Impact factor: 2.882

Review 5.  Stroke and Death Prediction with the Impact of Vascular Disease in Patients with Atrial Fibrillation.

Authors:  Abhishek Maan; Amir Y Shaikh; Moussa Mansour; Jeremy N Ruskin; E Kevin Heist
Journal:  J Atr Fibrillation       Date:  2012-06-15

Review 6.  Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference.

Authors:  Paulus Kirchhof; Gregory Y H Lip; Isabelle C Van Gelder; Jeroen Bax; Elaine Hylek; Stefan Kaab; Ulrich Schotten; Karl Wegscheider; Giuseppe Boriani; Axel Brandes; Michael Ezekowitz; Hans Diener; Laurent Haegeli; Hein Heidbuchel; Deirdre Lane; Luis Mont; Stephan Willems; Paul Dorian; Maria Aunes-Jansson; Carina Blomstrom-Lundqvist; Maria Borentain; Stefanie Breitenstein; Martina Brueckmann; Nilo Cater; Andreas Clemens; Dobromir Dobrev; Sergio Dubner; Nils G Edvardsson; Leif Friberg; Andreas Goette; Michele Gulizia; Robert Hatala; Jenny Horwood; Lukas Szumowski; Lukas Kappenberger; Josef Kautzner; Angelika Leute; Trudie Lobban; Ralf Meyer; Jay Millerhagen; John Morgan; Felix Muenzel; Michael Nabauer; Christoph Baertels; Michael Oeff; Dieter Paar; Juergen Polifka; Ursula Ravens; Ludger Rosin; W Stegink; Gerhard Steinbeck; Panos Vardas; Alphons Vincent; Maureen Walter; Günter Breithardt; A John Camm
Journal:  Europace       Date:  2011-07-26       Impact factor: 5.214

7.  Pentraxin 3 is a local inflammatory marker in atrial fibrillation.

Authors:  Takeshi Soeki; Sachiko Bando; Etsuko Uematsu; Tomomi Matsuura; Toshiyuki Niki; Takayuki Ise; Kenya Kusunose; Junko Hotchi; Yuka Ueda; Noriko Tomita; Koji Yamaguchi; Shusuke Yagi; Daiju Fukuda; Yoshio Taketani; Takashi Iwase; Hirotsugu Yamada; Tetsuzo Wakatsuki; Michio Shimabukuro; Masataka Sata
Journal:  Heart Vessels       Date:  2013-08-27       Impact factor: 2.037

8.  The expression levels of plasma micoRNAs in atrial fibrillation patients.

Authors:  Zheng Liu; Cheng Zhou; Yuzhou Liu; Sihua Wang; Ping Ye; Xiaoping Miao; Jiahong Xia
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

Review 9.  Potential Biological Markers of Atrial Fibrillation: A Chance to Prevent Cryptogenic Stroke.

Authors:  István Szegedi; László Szapáry; Péter Csécsei; Zoltán Csanádi; László Csiba
Journal:  Biomed Res Int       Date:  2017-07-13       Impact factor: 3.411

10.  Induction of atrial fibrillation by neutrophils critically depends on CD11b/CD18 integrins.

Authors:  Kai Friedrichs; Matti Adam; Lisa Remane; Martin Mollenhauer; Volker Rudolph; Tanja K Rudolph; René P Andrié; Florian Stöckigt; Jan W Schrickel; Thorben Ravekes; Florian Deuschl; Georg Nickenig; Stephan Willems; Stephan Baldus; Anna Klinke
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.